NEW YORK, Sept 10 – Affymetrix said Monday that it had expanded its agreement to provide GlaxoSmithKline with its GeneChip technology.
Under the terms of the deal, Glaxo’s research centers will be able to receive customized GeneChip arrays in smaller format sizes, providing them with lower cost arrays for high-throughput studies.
The deal reflects a new Affymetrix effort to offer specialized arrays at reduced prices.
"GSK's broader adoption of Affymetrix' GeneChip technology validates our belief that the market is shifting towards pre-synthesized oligonucleotide arrays," Susan Siegel, president of Affymetrix, said in a statement.
"By leveraging our unique and flexible wafer-based manufacturing process, we are able to provide chips at the lowest cost per datapoint in the industry with content intended to meet specific needs," Siegel added.
Financial terms of the deal were not disclosed.